Načítá se...
Moving Beyond Surrogate Endpoints in Cell Therapy Trials for Heart Disease
Cell therapy for heart disease began clinically more than a decade ago. Since then, numerous trials have been performed, but the studies have been underpowered, focusing primarily on low-risk patients with a recent myocardial infarction. Many data have accumulated on surrogate endpoints such as ejec...
Uloženo v:
| Hlavní autoři: | , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
AlphaMed Press
2014
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3902289/ https://ncbi.nlm.nih.gov/pubmed/24292794 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5966/sctm.2013-0104 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|